Provided by Business Wire BIOCORP: Full-Year 2020 Financial Results and Outlook for 2021 Business activity maintained with a very slight increase in revenues to nearly €8.5 million Sustained growth investments and net income in loss of €1.24 million Cash position strengthened to €4.9 million Continuation of the partnership strategy at high levels Strong outlook with full-scale commercial launch of Mallya Regulatory News: BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible PEA PME), a French company specialized in the design, development and manufacturing of innovative medical devices, today announces its annual results for the year ended on December 31, 2020, as approved by the Board of directors on April 6th.